Immunovant, Inc. (IMVT)
NASDAQ • Healthcare
Last close at October 22, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 9
in 17 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Immunovant’s EPS of -$0.75 trailed the -$0.63 estimate, -19%, while revenue of $7.1 million was in line with the $7.1 million consensus for the first fiscal quarter of 2027, reported on Aug. 6, 2026. Operating income was negative about $153.2 million, and net income was a loss of about $153.2 million, down 27% from a $120.6 million loss a year ago. Next-period consensus calls for EPS of -$0.73 on revenue of $7.1 million.
Next report — what to expect
Immunovant, Inc. (IMVT) reports earnings on November 9, 2026. Wall Street expects EPS of -$0.73 on revenue of $7.1 million. Heading into the release, note that Immunovant has beaten EPS in 3 of 8 most recent quarters, which may frame expectations around any variance versus consensus.
About Immunovant, Inc.
Immunovant, Inc. is a NASDAQ-listed biotechnology company in the healthcare sector that develops antibody therapies for autoimmune disease. In qualitative terms, it is a clinical-stage business rather than a commercial drug company. The company came public in 2019 and is based in New York City, New York.
Today's Snapshot
So far today, IMVT is trading 2.5% lower at 28.38, in line with a weaker sector.
Trading Volume
Below 10d avg (1.4M)
272.5K
vs S&P 500 Today
Underperforming Market
-2.07%
Updated: October 23, 2026 at 19:08 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$28.87 - $34.46Sell
- RSI (14)31.82Neutral
- Stochastic %K (14, 3, 3)30.71Neutral
- MACD Level (12, 26)-2.21Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.